Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

33.00 +1.07 (+3.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,231,875
Open 32.73
Bid (Size) 33.00 (2)
Ask (Size) 33.44 (2)
Prev. Close 31.93
Today's Range 31.80 - 33.53
52wk Range 15.81 - 41.06
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire

Performance

YTD
+24.48%
+24.48%
1 Month
+13.60%
+13.60%
3 Month
+81.42%
+81.42%
6 Month
+37.44%
+37.44%
1 Year
-14.99%
-14.99%

More News

Read More
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
Via InvestorPlace
3 Precision Medicine Stocks Tailoring Treatments
Via InvestorPlace
Assessing Guardant Health: Insights From 7 Financial Analysts
Via Benzinga
Where Guardant Health Stands With Analysts
Via Benzinga
Evaluating Guardant Health: Insights From 5 Financial Analysts
Via Benzinga
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
The 3 Best Personalized Medicine Stocks to Buy in July 2024
Via InvestorPlace
From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch
Via InvestorPlace
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
From Guardant Health, Inc.
Via Business Wire
Guardant Health Named to TIME100 Most Influential Companies
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
Via Benzinga
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
Via Benzinga
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
Via Benzinga
Exposures Product Safety
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
Via Investor's Business Daily
Exposures Product Safety
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
From Guardant Health, Inc.
Via Business Wire
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.